ThioMatrix Forschungs- und Beratungs GmbH

ThioMatrix Forschungs- und Beratungs GmbH (commonly ThioMatrix) is an Austrian pharmaceutical research and development company based in Innsbruck. It describes itself as "The Drug Delivery Network" and specializes in the development of non-invasive drug delivery systems. Its core proprietary platforms are Thiomer Technology and Self-Emulsifying Drug Delivery Systems (SEDDS) Technology, which are designed to improve the bioavailability and therapeutic performance of drugs that are otherwise difficult to administer non-invasively. The company positions its technologies for therapeutic peptides, peptidomimetics, nucleotides (DNA- and RNA-based drugs), Class II, III and IV drugs under the Biopharmaceutical Classification System (BCS), and drugs that are substrates of efflux pumps such as anticancer agents. ThioMatrix supports pharmaceutical and biotechnology partners across the development pipeline, from concept and preclinical research through to clinical trials, combining in-house expertise with a network of partnerships and collaborations with hospitals, veterinary institutions, CROs, and universities. According to its website, ThioMatrix has more than 20 years of experience, a team of more than 10 co-workers, over 100 collaborations, and more than 500 performed projects, along with 5+ awards and 10+ project grants. The company is led by founder and Chief Scientific Officer Prof. Dr. Andreas Bernkop-Schnürch, a Full Professor of Pharmaceutical Technology and author of more than 600 research and review articles in drug delivery, and Managing Director Dr. Simona Summonte. Its team also includes analytical development and project management specialists. ThioMatrix operates as a private company and is not listed on a stock exchange. Its activities bridge academic research and commercial pharmaceutical development, and its founder received the Tyrolean Provincial Science Award 2023, endowed with €14,000, recognizing his scientific contributions and entrepreneurial activity in the pharmaceutical sector.

ThioMatrix Forschungs- und Beratungs GmbH is an Austrian research and development company headquartered in Innsbruck, in the heart of the Alps. It was founded by Prof. Dr. Andreas Bernkop-Schnürch, a Full Professor of Pharmaceutical Technology at the University of Innsbruck and a prolific researcher in drug delivery with more than 600 research and review articles to his name. The company was established to translate academic advances in polymer-based and lipid-based drug delivery into practical formulation solutions for the pharmaceutical and biotechnology industries. ThioMatrix built its business around two proprietary technology platforms. The first, Thiomer Technology, is based on thiolated polymers (thiomers) designed to enhance the transport and uptake of active ingredients across biological barriers. The second, Self-Emulsifying Drug Delivery Systems (SEDDS) Technology, addresses the formulation challenges of poorly soluble drugs. Together, these platforms target the non-invasive administration of therapeutic peptides, peptidomimetics, nucleotides including DNA- and RNA-based drugs, BCS Class II, III and IV drugs, and efflux-pump substrate drugs such as anticancer agents. Over more than two decades of operation, the company reports having accumulated 20+ years of experience, completed 500+ projects, and established 100+ collaborations. Its network includes hospitals, veterinary institutions, contract research organizations (CROs), and universities, enabling it to support partners from preclinical research through clinical trials. This integrated approach is intended to accelerate time to market and produce delivery systems tailored to specific therapeutic candidates. The company is led by its founder as Chief Scientific Officer, with Dr. Simona Summonte serving as Managing Director and overseeing acquisitions, business development, organizational development, regulatory affairs, and employee relations. The team includes specialists in analytical development and project management, with expertise spanning chemistry, pharmacy, and pharmaceutical technology. In 2023, Prof. Dr. Bernkop-Schnürch received the Tyrolean Provincial Science Award, endowed with €14,000, presented at the Landhaus in Innsbruck. The award recognized his scientific contributions, his role in strengthening the international reputation of the Institute of Pharmacy at the University of Innsbruck, and his success as an entrepreneur bridging academic research and practical application. ThioMatrix continues to operate as a private, independent company offering drug delivery development services and technology platforms to partners worldwide.

• ThioMatrix founded by Prof. Dr. Andreas Bernkop-Schnürch (exact year not specified in sources)

• Company reports 20+ years of experience, 500+ performed projects, and 100+ collaborations

• Prof. Dr. Andreas Bernkop-Schnürch receives the Tyrolean Provincial Science Award 2023, endowed with €14,000

A specialized drug delivery R&D partner for pharma and biotech, bridging academic research and clinical application through proprietary Thiomer and SEDDS platforms.

• Thiomer Technology

  Proprietary platform based on thiolated polymers for non-invasive drug delivery, enhancing transport across biological barriers.

• SEDDS Technology

  Self-Emulsifying Drug Delivery Systems platform for improving the bioavailability of poorly soluble drugs.

1. 1Thiomatrix - The Drug Delivery Networkthiomatrix.com
2. 2ThioMatrix - About usthiomatrix.com
3. 3ThioMatrix- Science Award of Tyrol 2023thiomatrix.com
4. 4ThioMatrix Forschungs- und Beratungs GmbH - Wikidatawikidata.org